Researchers at the Institute of Functional Genomics in Montpellier, France, have developed nanobodies derived from llama antibodies that could revolutionize the treatment of schizophrenia. This new molecule is capable of activating brain receptors and crossing the blood-brain barrier, making it a superior alternative to current treatments.

Thus, llama antibodies could be used to create a new generation of treatments for schizophrenia. They reveal that the new molecule can be injected into veins or muscles and has demonstrated its ability to cross the protective blood-brain barrier and effectively reach brain cell receptors.

According to the study, the new nanobody is more effective than the antibodies currently used in the treatment of schizophrenia. In addition, it is biodegradable and has few side effects.

“There is an urgent need for efficient and innovative therapies to treat brain disorders such as psychiatric and neurodegenerative diseases,” the study authors wrote.

Notably, immunotherapies have proven effective in many medical areas, but have not been considered for treating brain diseases due to poor immunoglobulin penetration into the brain.

Schizophrenia, which affects approximately 1% of Americans, can cause a variety of psychological symptoms related to thought processes, perceptions, emotional responsiveness, and social interactions.

Comparison with existing treatments

Current treatments for schizophrenia, which include medications and talking therapies, primarily focus on symptom reduction. However, they have a limited impact on cognitive deficits.

The new nanobodies have been shown to improve brain function in animal models from the first injection, suggesting significant potential for addressing these limitations.

Future Implications

Despite promising results in animals, additional research is still needed to validate the safety and effectiveness of these nanobodies in humans.

Production of high-quality, large volumes is essential to move toward clinical trials. Researchers are seeking to collaborate with companies or investors to continue the development of this new therapeutic strategy.

Potential beyond schizophrenia

The discovery of nanobodies as a therapeutic tool is not only limited to schizophrenia, but also opens up the possibility of developing treatments for other neurological diseases, making this approach an important step towards innovation in mental health.